According to 2017 European LeukemiaNet (ELN) recommendations, mutant NPM1 gene with wild type FLT3-ITD or low allele burden of FLT3-ITD mutation and bi-allelic CEBPA mutation are considered to be the favorable prognostic risk stratification for AML, whereas high allele burden of FLT3-ITD mutation with or without mutant NPM1 is classified as intermediate and unfavorable risk, respectively. This evidence concerns the gene FLT3 and acute myeloid leukemia.